Tissue variation of acute haemodynamic changes by N(G)-nitro-L-arginine in stroke-prone spontaneously hypertensive and Wistar-Kyoto rats

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 3-4, 1997, Pages 249-255

  Higashino, H ^a   Simeonova, K ^b   Lambev, I ^b   Suzuki, A ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Brain; Inhibitors; Microspheres; N(G) nitro L arginine; Nitric oxide; Rats; Regional blood flow; Stroke prone spontaneously hypertensive rats; Wistar Kyoto rats

Indexed keywords

N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD FLOW; ENZYME INHIBITION; HEART OUTPUT; HEMODYNAMICS; HYPERTENSION; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR RESISTANCE; VASODILATATION;

EID: 0030898610     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb01815.x     Document Type: Article

References (33)

1. Rees DD, Palmer RMJ, Schulz R, Hudson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 1990; 101: 746-52.
2. G-nitro-L-arginine and L-arginine on regional cerebral blood flow in the cat. J. Physiol. 1942; 449: 183-96.
3. G-nitro-arginine. Br. J. Pharmacol. 1991; 102: 565-6.
4. G-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br. J. Pharmacol. 1992; 105: 653-6.
5. Kozniewska E, Oseka M, Stys T. Effects of endothelium-derived nitric oxide on cerebral circulation during normoxia and hypoxia in the rat. J. Cereb. Blood Flow Metab. 1992; 12: 311-17.
6. Toda N, Okamura T. Reciprocal regulation by putatively nitroxidergic and adrenergic nerves of monkey and dog temporal arterial tone. Am. J. Physiol. 1991; 261: H1740-5.
7. Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ. Res. 1974; 34-35 (Suppl. I): I-143-53.
8. Nakai M, Tamaki K, Yamamoto J, Shimouchi A, Maeda M. A minimally invasive technique for multiple measurement of regional blood flow of the rat brain using radiolabeled microspheres. Brain Res. 1990; 507: 168-71.
9. Bollman LJ, Cain C, Grindlay JH. Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J. Lab. Clin. Med. 1948; 33: 1349-52.
10. Moncada S, Palmer RMJ, Higgs EA. Biosynthesis of nitric oxide from L-arginine: A pathway for the regulation of cell function and communication. Biochem. Pharmacol. 1989; 38: 1709-15.
11. Toda N, Okamura T. Endothelium-dependent and -independent responses to vasoactive substances of isolated human coronary arteries. Am. J. Physiol. 1989; 257: H988-95.
12. Ahlner J, Andersson RGG, Torfgård K, Axelsson KL. Organic nitrate esters: Clinical use and mechanism of actions. Pharmacol. Rev. 1991; 43: 351-423.
13. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl Acad. Sci. USA 1990; 87: 682-5.
14. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
15. Drexler H, Hablawetz E, Lu W, Riede U, Christers A. Effects of inhibition of nitric oxide formation on regional blood flow in experimental myocardial infarction. Circulation 1992; 86: 255-62.
16. Greenblatt EP, Loeb AL, Longnecker DE. Marked regional heterogeneity in the magnitude of EDRF/NO-mediated vascular tone in awake rats. J. Cardiovasc. Pharmacol. 1993; 21: 235-40.
17. Wang Y-X, Gavras I, Wierzba T, Lammek B, Gavras H. Inhibition of nitric oxide, bradykinin, and prostaglandins in normal rats. Hypertension 1992; 19 (Suppl. II): II-255-61.
18. Faraci FM, Heistad DD. Endothelium-derived relaxing factor inhibits constrictor responses of large cerebral arteries to serotonin. J. Cereb. Blood Flow Metab. 1992; 12: 500-6.
19. G-nitro-L-arginine on cerebral blood flow response to changes in carbon dioxide tension. J. Cereb. Blood Flow Metab. 1992; 12: 947-53.
20. G-nitro-L-arginine methylester are conserved under halothane anesthesia. Eur. J. Pharmcol. 1993; 249: 7-11.
21. G-nitro-L-arginine methyl ester on the cardiovascular system of the anaesthetized rabbit and on the cardiovascular response to thyrotropin-releasing hormone. Br. J. Pharmacol. 1993; 109: 1219-25.
22. Talman WT, Dragon DN. Inhibition of nitric oxide synthesis extends cerebrovascular autoregulation during hypertension. Brain Res. 1995; 672: 48-54.
23. Gonzalez ER, Krieger AJ, Sapru HN. Central resetting of baroreflex in the spontaneously hypertensive rat. Hypertension 1983; 5: 346-52.
24. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 1994; 265: 1883-5.
25. Kovách AGB, Lohinai Z, Marczis J, Balla I, Dawson TM, Snyder SH. The effect of hemorrhagic hypotension and retransfusion and 7-nitroindazole on rCBF, NOS catalytic activity, and cortical NO content in the cat. Ann. N.Y. Acad. Sci. 1994; 738: 348-68.
26. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn. Circ. J. 1963; 27: 282-93.
27. Ferrone RA, Walsh GM, Tsuchiya M, Frorlich ED. Comparison of hemodynamics in conscious spontaneous and renal hypertensive rats. Am. J. Physiol. 1979; 236: H403-8.
28. Pfeffer MA, Frohlich ED, Pfeffer JM, Weiss AK. Pathophysiological implications of the increased cardiac output of young spontaneously hypertensive rats. Circ. Res. 1974; 34-35 (Suppl. I): I-235-42.
29. Lundin, SA, Hallbäck-Nordlander M. Background of hyperkinetic circulatory state in young spontaneously hypertensive rats. Cardiovasc. Res. 1980; 14: 561-7.
30. G-monomethyl-L-arginine in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Br. J. Pharmacol. 1991; 102: 823-6.
31. G-nitro-L-arginine methyl ester. J. Hypertens. 1991; 9 (Suppl. 6): S192-3.
32. Tagami M, Ikeda K, Nara Y et al. Detailed examination of vascular lesions triggered by an inhibitor of endothelium-derived relaxing factor. Lab. Invest. 1995; 72: 174-82.
33. G-nitro-L-arginine methyl ester, and NO-donor, glyceryl trinitrate, in conscious SHRSP and WKY. Clin. Exp. Pharmacol. Physiol. 1995; 22 (Suppl. 1): S151-3.